ClinicalTrials.gg
RecruitingNCT01763125Updated Mar 23, 2023

Establishment of a Tumor Bank for Blood Samples

An observational study in Ovarian Neoplasms, Breast Neoplasms and Colorectal Neoplasms, sponsored by Medical University of Vienna. Recruiting at 6 sites in 4 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-23.

Sponsored by Medical University of Vienna · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Other
Enrollment
10,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 189 studies in Ovarian Neoplasms with a site in Germany — 34 open to participants now, 54 under way, 19 of them phase 3. Ovarian Neoplasms · Germany.

Planned enrollment
2nd of 23
10,000 · median 530
Started
2003
with 4 others
Observational
23 of 189
6 open now
Primary completion
2026-12
later than 13 of 53 live
Registered
73rd of 189
by date
Lead sponsor
5 of 189
Medical University of Vienna

Among the 189 studies in Ovarian Neoplasms with a site in Germany, this one is the 2nd largest by planned enrollment of the 23 observational ones that give a count, is one of 5 that started in 2003, is one of 23 observational ones, reaches primary completion later than 13 of the 53 other live ones, and was the 73rd registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

34 of the 189 studies in Ovarian Neoplasms with a site in Germany are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 189 studies in Ovarian Neoplasms with a site in Germany, or all of them as a file.
02

Study summary

Establishment of a tumor bank, consisting of blood samples of tumor patients and healthy people as controls. The blood samples will be collected systematically together with the corresponding clinical data. The biological samples, the clinical date together with prospective experimental date constitute the entity of the tumor bank.

Read the detailed description

Recent progress in diagnosis and therapy of cancer diseases can be ascribed mainly to translational research. The relevance of "translational oncology" will only increase in the future -"From bench to bedside" - the swift implementation of new science research results in clinical studies in order to expedite progress in clinical cancer therapy for the benefit of the patient.

Its almost a matter of course in the medical science today to collect biological samples together with clinical information thereby creating the foundation for future excellent fundamental research.

The aim of this tumor bank is to consist of biological samples (together with a tissue bank - see EK 260/2003) and isolates of tumor patients and healthy people as controls. The biological samples, the clinical date together with prospective experimental date constitute the entity of the tumor bank. The content of the tumor bank can provide essential material for current and future research (e.g. analyses of prognostic or predictive tumor markers; genetically analysis (polymorphism, mutation, hypermethylation; verification and characterisation of disseminated tumor cells).

03

Conditions studied

  • Ovarian Neoplasms
  • Breast Neoplasms
  • Colorectal Neoplasms
  • Neoplasms of the Female Genitalia
  • Lung Neoplasms
  • Endocrine Gland Neoplasms

Keywords

  • circulating tumor cells
  • CTC
  • tumor marker
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

  • Male and female patients/people.
  • Minimum age 18 years
  • Characteristics: Recruited at the Medical University Vienna or at one of the facilities cooperating with the Vienna Med. University

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male/Female
  • Age 18 to 90 years max.
  • Just one current known malignant disease or
  • Just one current inflammatory disease

Exclusion criteria

Exclusion Criteria:

  • Inflammatory disease and malignant disease
  • multiple
  • multiple diseases
  • underage
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Case-control
Time perspective
Other
Enrollment
10,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Malignant tumors

    Patients who have one of the Neoplasms stated above under "conditions". Blood samples will be taken.

    Other: Blood collection

  • Benign controls

    Patients with a benign tumor or an inflammatory disease - to be matched by age and affected organ with a patient with a malignant disease. Blood samples will be taken.

    Other: Blood collection

  • Healthy controls

    People/patients who have no known disease at time of blood sampling or are admitted to the hospital for minor interventions and have no inflammatory disease. Blood samples will be taken.

    Other: Blood collection

Interventions

  • OtherBlood collection

    Blood sample is collected during routine blood collection by a medical doctor. No more than 60ml (max.) at one timepoint.

06

What researchers measure

Primary outcomes

  1. Establishment of blood/tissue bank consisting of oncological samples from cancer patients and benign and healthy controls.

    Time frame: 14 years

07

Study locations

1 of 6 sites recruiting
  • Innsbruck Medical University
    Innsbruck, 6020, Austria
    Completed

    Not enrolling at this site.

  • University Hospitals Leuven - Department of Obstetrics and Gynaecology
    Leuven, 3000, Belgium
    Completed

    Not enrolling at this site.

  • Charité University - Campus Virchow Chlinic
    Berlin, 13353, Germany
    Recruiting
  • University Medical Center Freiburg
    Freiburg, 79106, Germany
    Completed

    Not enrolling at this site.

  • University Clinic of Ruhr University Bochum
    Herne, 44626, Germany
    Completed

    Not enrolling at this site.

  • European Institute of Oncology, Division of Gynecologic Oncology, Unit of Preventive Gynecology
    Milan, 20100, Italy
    Withdrawn

    Not enrolling at this site.

08

References and documents

Publications

  • Hefler LA, Concin N, Hofstetter G, Marth C, Mustea A, Sehouli J, Zeillinger R, Leipold H, Lass H, Grimm C, Tempfer CB, Reinthaller A. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res. 2008 Feb 1;14(3):710-4. doi: 10.1158/1078-0432.CCR-07-1044. PubMed 18245530 ↗
  • Konigsberg R, Gneist M, Jahn-Kuch D, Pfeiler G, Hager G, Hudec M, Dittrich C, Zeillinger R. Circulating tumor cells in metastatic colorectal cancer: efficacy and feasibility of different enrichment methods. Cancer Lett. 2010 Jul 1;293(1):117-23. doi: 10.1016/j.canlet.2010.01.003. Epub 2010 Feb 18. PubMed 20167419 ↗
  • Obermayr E, Sanchez-Cabo F, Tea MK, Singer CF, Krainer M, Fischer MB, Sehouli J, Reinthaller A, Horvat R, Heinze G, Tong D, Zeillinger R. Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients. BMC Cancer. 2010 Dec 3;10:666. doi: 10.1186/1471-2407-10-666. PubMed 21129172 ↗
  • Konigsberg R, Obermayr E, Bises G, Pfeiler G, Gneist M, Wrba F, de Santis M, Zeillinger R, Hudec M, Dittrich C. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. Acta Oncol. 2011 Jun;50(5):700-10. doi: 10.3109/0284186X.2010.549151. Epub 2011 Jan 24. PubMed 21261508 ↗
  • Obermayr E, Castillo-Tong DC, Pils D, Speiser P, Braicu I, Van Gorp T, Mahner S, Sehouli J, Vergote I, Zeillinger R. Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortium. Gynecol Oncol. 2013 Jan;128(1):15-21. doi: 10.1016/j.ygyno.2012.09.021. Epub 2012 Sep 24. PubMed 23017820 ↗
  • Hasenburg A, Eichkorn D, Vosshagen F, Obermayr E, Geroldinger A, Zeillinger R, Bossart M. Biomarker-based early detection of epithelial ovarian cancer based on a five-protein signature in patient's plasma - a prospective trial. BMC Cancer. 2021 Sep 16;21(1):1037. doi: 10.1186/s12885-021-08682-y. PubMed 34530759 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2003, a primary completion of Dec 2026 and a completion of Dec 2026. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2013
First posted
Jan 8, 2013
Start
Nov 2003
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Mar 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01763125
Responsible party
Robert Zeillinger, Dr.phil. (Prof. Dr., Medical University of Vienna) — Principal investigator
First posted
Jan 8, 2013
Start date
Nov 2003
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Mar 23, 2023

Study contacts

Robert Zeillinger, Prof. Dr.
Contact
robert.zeillinger@meduniwien.ac.at
+43140400 ext. 78310
Eva Obermayr, PhD
Contact
eva.obermayr@muv.ac.at
+43140400 ext. 78270
Robert Zeillinger, Prof.Dr.
principal investigator · Medical University Vienna, Dept. of Obstetrics & Gynaecology

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion